ArticleBMC infectious diseases2025
Applying novel Plasmodium Vivax serological exposure markers to quantify residual malaria transmission in the Philippines through repeated health facility surveys: the SMaRT study protocol.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Malaria serology for surveillance, insights into immunity, and vaccine development.Infection and immunity · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAfter decades of progress towards malaria elimination, Plasmodium vivax is now the predominant source of infection and the major obstacle towards elimination in the Asia-Pacific region. In the Philippines, the situation is slightly different with P. falciparum still accounting for the largest burden. However, there has been a steady increase in the total number of reported P. vivax cases in the main transmission hotspot of Palawan, as well as two years of consecutive outbreaks of P. vivax in the near-elimination setting of Sultan Kudarat. Here, we describe the protocol for a new study in Sultan Kudarat that aims to identify whether an underlying, hidden, burden of P. vivax contributes to the ongoing risk of outbreaks.
methodsA challenge for surveillance of P. vivax is the presence of an additional hidden liver-stage, where parasites (hypnozoites) lie dormant for weeks to months before causing a relapse of infection. Hypnozoites cannot be detected with commercial diagnostic tests. We have designed novel serological exposure markers of recent P. vivax infection, which indirectly inform on hypnozoite carriage. In this study we will conduct a prospective 18-month survey in health facilities within Kalamansig, Sultan Kudarat, and compare epidemiology and serological data with that in archival samples from Palawan. We will enroll both care-seeking individuals and their companions, and utilise remote geolocation to uncover spatial trends. DISCUSSION: This study will generate important data for the malaria control program in the Philippines whilst also demonstrating utility of P. vivax serological exposure markers in near-elimination settings. We will utilise this data to build a decision-making framework to support novel, evidence-based elimination strategies relevant for the Philippines and the wider Asia-Pacific region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.